Picture of Jubilant Pharmova logo

JUBLPHARMA — Jubilant Pharmova Income Statement

0.000.00%
in flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Annual income statement for Jubilant Pharmova, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

2022
March 31st
2023
March 31st
2024
March 31st
2025
March 31st
2026
March 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSARS
Standards:
IAS
IAS
IAS
IAS
IAS
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue61,30262,81767,02972,34582,796
Cost of Revenue
Gross Profit42,08938,92241,31944,68651,330
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses53,05761,08763,48760,68275,194
Operating Profit8,2451,7303,54211,6637,602
Total Net Non Operating Interest Income / Expense
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes6,3042781,7059,8066,141
Provision for Income Taxes
Net Income After Taxes4,130-6497278,3633,975
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income4,139-6107718,3943,985
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income4,139-6107718,3943,985
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS26.15.69.3933.527.5
Dividends per Share